AKTX-101 and Adagrasib Show Synergy in KRAS G12C/D Pancreatic Models, Outperforming TROP2 ADCs
AKTX•AKTX-101 plus the KRAS inhibitor adagrasib achieved synergistic cytotoxicity in KRAS G12C- and G12D-mutated pancreatic cancer models, while comparator TROP2 ADCs displayed antagonism. These findings support expanding the PH1 RNA spliceosome-modulating payload’s application beyond AKTX-101’s planned Phase 1 trial to tackle stubborn KRAS-driven tumors.
1. Preclinical Synergy Findings
In preclinical assays, AKTX-101 combined with the KRAS inhibitor adagrasib demonstrated potent synergistic cytotoxicity across pancreatic cancer cell lines harboring KRAS G12C and G12D mutations, whereas comparator TROP2 ADCs carrying Topoisomerase I payloads exhibited antagonistic effects when paired with adagrasib.
2. Payload Differentiation
The synergy appears linked to AKTX-101's PH1 payload, which modulates RNA spliceosome activity to degrade pre-mRNA transcripts, including mutant KRAS transcripts, differentiating it from conventional ADC payloads that rely on DNA or microtubule damage.
3. Development Timeline Outlook
These results support broadening the AKTX-101 development plan beyond the current Phase 1 target, with IND-enabling studies underway and a first-in-human trial expected by mid-2027 to explore combination strategies in KRAS-driven tumors.
